Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer.
Expert Rev Anticancer Ther
; 14(11): 1369-78, 2014 Nov.
Article
em En
| MEDLINE
| ID: mdl-24927631
ABSTRACT
After initial response to androgen receptor (AR) targeting drugs abiraterone or enzalutamide, most patients develop progressive disease and therefore, castration resistant prostate cancer remains a terminal disease. Multiple mechanisms underlying acquired resistance have been postulated. Intratumoral androgen synthesis may resume after abiraterone treatment. A point mutation in the ligand-binding domain of AR may confer resistance to enzalutamide. Emergence of AR splice variants lacking the ligand-binding domain may mediate resistance to abiraterone and enzalutamide. Steroid receptors such as glucocorticoid receptor may substitute for AR. Drugs with novel mechanisms of action or combination therapy, along with biomarkers for patient selection, may be needed to improve the therapy of castration resistant prostate cancer.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Receptores Androgênicos
/
Sistemas de Liberação de Medicamentos
/
Resistencia a Medicamentos Antineoplásicos
/
Antagonistas de Receptores de Andrógenos
/
Neoplasias de Próstata Resistentes à Castração
Limite:
Humans
/
Male
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article